dianicline

chemical compound

Uses your system voice; voice and rate in settings.

Q5271647Snapshot

≈ 1 min read

Names in other languages

  • Englishdianicline
  • shDianiklin
  • СрпскиDianiklin

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Dianicline (SSR-591,813) is a drug developed by Sanofi-Aventis which acts as a partial agonist at neural nicotinic acetylcholine receptors. It is subtype-selective, binding primarily to the α4β2 subtype. It is being developed as a medication for the treatment of nicotine dependence to assist in smoking cessation.

Dianicline is very similar to the already marketed drug varenicline and it is unclear what advantages it will have over the older drug, although it may have an improved side effect profile. It has been through human trials up to Phase II, although results have not yet been reported. Drug development has been discontinued after reporting of unfavourable results during Phase III trials.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1330796115 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.